
    
      All eligible patients will receive:

        -  Bevacizumab 15mg/kg IV infusion,Day 1

        -  Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1

        -  Carboplatin AUC 6.0 IV Day 1

        -  Erlotinib 150 mg by mouth daily

      The regimen will be repeated every 21 days for a total of 4 courses. Patients will be
      initially evaluated for response after completing 2 courses (6 weeks) of treatment. Patients
      with an objective tumor response or stable disease will continue treatment for another 2
      courses. Patients will be re-evaluated after 4 courses and those with objective tumor
      response or stable disease will stop chemotherapy with paclitaxel/carboplatin and continue
      treatment with bevacizumab/erlotinib until tumor progression is documented for a maximum of
      12 months. During treatment with bevacizumab/erlotinib response will be evaluated every 12
      weeks.
    
  